Pedro Exman
YOU?
Author Swipe
View article: Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study Open
gov number, NCT03749421.
View article: Figure S3 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Figure S3 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Case flow diagram of ILC cohort.
View article: Data from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Data from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Purpose:The prognostic utility of Breast Cancer Index (BCI) for risk assessment of overall (0–10 years), early (0–5 years), and late (5–10 years) distant recurrence (DR) in hormone receptor–positive (HR+) invasive lobular carcinoma (ILC) w…
View article: Figure S1 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Figure S1 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Flow diagram of pilot study comparing manual macro-dissection with laser capture microdissection.
View article: Figure S4 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Figure S4 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Prognostic performance of BCI for overall 10-year, early (0-5 years), and late (5-10 years) distant recurrence (DR) rate for patients that received adjuvant endocrine therapy in the lobular cohort.
View article: Table S1 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Table S1 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Clinicopathological characteristics by BCI risk groups.
View article: Table S2 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Table S2 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Number of overall 10-year, early (0-5 years), and late (5-10 years) distant recurrences (DR) by prespecified BCI risk groups for patients with N0 tumors, N+ tumors, and the overall cohort (N0 and N+).
View article: Figure S5 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Figure S5 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Patient distribution of BCI predictive [BCI (H/I)-Low vs. -High] and BCI prognostic groups (BCI Prognostic Low/Intermediate vs. High).
View article: Figure S2 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Figure S2 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Concordance of BCI scores between manual microdissection versus laser capture microdissection (A) and the relationship of BCI score difference versus tumor content (B).
View article: Figure S6 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
Figure S6 from Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma Open
Prognostic performance of BCI (gene expression only) and BCIN+ (gene expression plus tumor size and grade) for overall 10-year, early (0-5 years), and late (5-10 years) distant recurrence rate in patients with (A) N0 and (B) N+ tumors, res…
View article: USE OF REPOURPOSED DRUGS LOSARTAN AND IVERMECTIN IN PATIENTS WITH CANCER FOR PREVENTION OF COVID-19 SERIOUS EVENTS DURING PANDEMIC. A randomized, double-blind, placebo-controlled phase II study.
USE OF REPOURPOSED DRUGS LOSARTAN AND IVERMECTIN IN PATIENTS WITH CANCER FOR PREVENTION OF COVID-19 SERIOUS EVENTS DURING PANDEMIC. A randomized, double-blind, placebo-controlled phase II study. Open
Introduction: Cancer patients are at higher risk of COVID-19 severe complications and also demonstrated a lower antibodies conversion after vaccination. Therefore, therapeutic approaches after COVID-19 infection are needed in this populati…
View article: Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Supplementary Methods
View article: Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and t…
View article: Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Supplementary Tables
View article: Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced local recurrence only after treatment for early stage breast cancer. cfDNA time points for all patients who experienced local recurrence only. End points represent time of last follow up or death.
View article: Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who were recurrence free after treatment for early stage breast cancer. cfDNA time points for all patients who did not experienced recurrence. Those marked with poor detection limits had an estimated detection limit worse than 1/1…
View article: Supplemental Table 3 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer
Supplemental Table 3 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer Open
FGFR alterations in different cohorts
View article: Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Overview schematic of MRD assay. MRD assay workflow from characterizing a primary tumor to determining if a blood draw contains evidence of residual disease.
View article: Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Technical performance of the MRD Assay. All samples from early stage breast cancer cohort. Includes plasma cfDNA and buffy coat gDNA samples. Samples from the same patient and probed with the same panel are represented independently. (A) O…
View article: Supplemental Table 8 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer
Supplemental Table 8 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer Open
Foundation Medicine cohort
View article: eTable1 from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
eTable1 from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer Open
Baseline characteristics for PD-L1 known cohort
View article: Supplemental Table 13 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer
Supplemental Table 13 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer Open
RNA-seq under drug treatment
View article: Data from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Data from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer Open
Purpose:Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burd…
View article: eFigure5 from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
eFigure5 from Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer Open
Kaplan-Meier curves for overall survival for high TMB {greater than or equal to}7 and {greater than or equal to}10 mutations/Mb and PTEN alterations in non-ICI-treated mTNBC. Overall survival by (A) tumor mutational burden
View article: Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and t…
View article: Supplemental Table 10 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer
Supplemental Table 10 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer Open
Gene sets defined and used in this study and Signature strength per sample
View article: Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced distant recurrence after treatment for early stage breast cancer. cfDNA time points for patients who ultimately experienced distant recurrence. Those marked with poor detection limits had an estimated detection lim…
View article: Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Early stage breast cancer cohort. (A) Overview of subtype distribution of cohort as well as the timing of blood draws relative to surgery and treatment. (B) REMARK diagram of the early stage breast cancer cohort. (C) Distribution of the nu…
View article: Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Patients who experienced distant recurrence after treatment for early stage breast cancer. cfDNA time points for patients who ultimately experienced distant recurrence. Those marked with poor detection limits had an estimated detection lim…
View article: Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Open
Early stage breast cancer cohort. (A) Overview of subtype distribution of cohort as well as the timing of blood draws relative to surgery and treatment. (B) REMARK diagram of the early stage breast cancer cohort. (C) Distribution of the nu…